Literature DB >> 25449842

Striatal dopamine receptor plasticity in neurotensin deficient mice.

Lucy G Chastain1, Hongyan Qu2, Chase H Bourke2, P Michael Iuvone3, Paul R Dobner4, Charles B Nemeroff5, Becky Kinkead2.   

Abstract

Schizophrenia is thought to be caused, at least in part, by dysfunction in striatal dopamine neurotransmission. Both clinical studies and animal research have implicated the dopamine neuromodulator neurotensin (NT) in the pathophysiology of schizophrenia. Utilizing male mice lacking the NT gene (NT(-/-)), these studies examined the consequences of NT deficiency on dopaminergic tone and function, investigating (1) dopamine concentrations and dopamine receptor and transporter expression and binding in dopaminergic terminal regions, and (2) the behavioral effects of selective dopamine receptor agonists on locomotion and sensorimotor gating in adult NT(-/-) mice compared to wildtype (NT(+/+)) mice. NT(-/-) mice did not differ from NT(+/+) mice in concentrations of dopamine or its metabolite DOPAC in any brain region examined. However, NT(-/-) mice showed significantly increased D1 receptor, D2 receptor, and dopamine transporter (DAT) mRNA in the caudate putamen compared to NT(+/+) controls. NT(-/-) mice also showed elevated D2 receptor binding densities in both the caudate putamen and nucleus accumbens shell compared to NT(+/+) mice. In addition, some of the behavioral effects of the D1-type receptor agonist SKF-82958 and the D2-type receptor agonist quinpirole on locomotion, startle amplitude, and prepulse inhibition were dose-dependently altered in NT(-/-) mice, showing altered D1-type and D2-type receptor sensitivity to stimulation by agonists in the absence of NT. The results indicate that NT deficiency alters striatal dopamine receptor expression, binding, and function. This suggests a critical role for the NT system in the maintenance of striatal DA system homeostasis and implicates NT deficiency in the etiology of dopamine-associated disorders such as schizophrenia.
Copyright © 2014. Published by Elsevier B.V.

Entities:  

Keywords:  Dopamine; Dopamine receptor; Neurotensin; Schizophrenia; Striatum

Mesh:

Substances:

Year:  2014        PMID: 25449842      PMCID: PMC4496790          DOI: 10.1016/j.bbr.2014.11.014

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  60 in total

1.  The neurotensin receptor antagonist, SR48692, attenuates the expression of amphetamine-induced behavioural sensitisation in mice.

Authors:  F G Costa; R Frussa-Filho; L F Felicio
Journal:  Eur J Pharmacol       Date:  2001-09-28       Impact factor: 4.432

2.  Amphetamine-elicited striatal Fos expression is attenuated in neurotensin null mutant mice.

Authors:  Jim Fadel; Paul R Dobner; Ariel Y Deutch
Journal:  Neurosci Lett       Date:  2006-04-24       Impact factor: 3.046

3.  Increased abundance of alternatively spliced forms of D2 dopamine receptor mRNA after denervation.

Authors:  K A Neve; R L Neve; S Fidel; A Janowsky; G A Higgins
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-01       Impact factor: 11.205

4.  Dopamine control of striatal gene expression during development: relevance to knockout mice for the dopamine transporter.

Authors:  V Fauchey; M Jaber; B Bloch; C Le Moine
Journal:  Eur J Neurosci       Date:  2000-09       Impact factor: 3.386

5.  Amphetamine and negative symptoms of schizophrenia.

Authors:  M Sanfilipo; A Wolkin; B Angrist; D P van Kammen; E Duncan; S Wieland; T B Cooper; E D Peselow; J Rotrosen
Journal:  Psychopharmacology (Berl)       Date:  1996-01       Impact factor: 4.530

6.  Effects of a novel neurotensin peptide analog given extracranially on CNS behaviors mediated by apomorphine and haloperidol.

Authors:  B Cusack; M Boules; B M Tyler; A Fauq; D J McCormick; E Richelson
Journal:  Brain Res       Date:  2000-02-21       Impact factor: 3.252

7.  Reduced CSF neurotensin concentration in drug-free schizophrenic patients.

Authors:  L H Lindström; E Widerlöv; G Bisette; C Nemeroff
Journal:  Schizophr Res       Date:  1988 Jan-Feb       Impact factor: 4.939

8.  CSF concentrations of neurotensin in schizophrenia: an investigation of clinical and biochemical correlates.

Authors:  N A Breslin; R L Suddath; G Bissette; C B Nemeroff; P Lowrimore; D R Weinberger
Journal:  Schizophr Res       Date:  1994-04       Impact factor: 4.939

Review 9.  Negative symptoms in schizophrenia: avolition and Occam's razor.

Authors:  George Foussias; Gary Remington
Journal:  Schizophr Bull       Date:  2008-07-21       Impact factor: 9.306

10.  D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride.

Authors:  L Farde; F A Wiesel; S Stone-Elander; C Halldin; A L Nordström; H Hall; G Sedvall
Journal:  Arch Gen Psychiatry       Date:  1990-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.